- Chief Executive Officer：
- Chizuko Koseki
Oligonucleotide based drug discovery platform to revolutionise expensive healthcare economy by discovering low cost, highly effective and safe medicines.
TAGCyx focuses on creating novel nucleic acid-based drugs for pharmaceutical applications through its revolutionary nucleic acid-based drug discovery platform, “Xenoligo system”. The platform enables the screening of drug candidates from large oligonucleotide libraries containing highly functional non-natural bases and their stability optimization. Xenoligo molecules possess high selectivity and affinity against their targets which provide significant advantages compared to conventional small-molecule and protein therapeutics.
With the vision to commercialize “Artificial base-pairing technology” and its application in a wide range of Life Science fields, TAGCyx was co-founded by Dr. Hirao Ichiro, former Leader of the RIKEN Synthetic Molecular Biology Team, and others in 2007. From 2016, TAGCyx targets drug discovery and development as their main focus.
Nucleic acid drugs can be created with unprecedented efficacy using the Xenoligo™ platform which possesses high affinity and selectivity for target substances.
UTEC’s value add
UTEC has supported TAGCyx for management structuring, fundraising, business alliances, etc.
Generation of Xenoligo molecules by SELEX